

UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 07-1052-WO-US)

IN RE APPLICATION OF:)
Brookings et al.)
)
Serial No. 10/561,052) Examiner: N. Rahmani
))
Filed: October 10, 2006) Group Art Unit: 1625
))
Int'l Serial) Confirmation No.: 3974
No.)
Title Thienopyridone Derivatives as Kinase Inhibitors)

STATEMENT OF SUBSTANCE OF THE INTERVIEW OF December 30, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

This Substance of the Interview is filed in response to the Interview Summary filed by the Examiner in this case on December 30, 2008.

Applicants agree with the substance of the Examiner's Interview Summary, dated February 6, 2009. During the interview on December 30, 2008, the applicants' representative discussed with the Examiner the allowability of all claims pending in the application, if Claim 12 was amended to read as follows:

12. (currently amended) A method for inhibiting p38-alpha MAP kinase which comprises administering to a patient in need thereof a compound of claim 1, or a pharmaceutically acceptable salt or N-oxide thereof.

Applicants agreed to this amendment. The applicant's representative also agreed to file a terminal disclaimer with respect to US 2006/0004025.

Date: February 23, 2009

Respectfully submitted,

/Marcia Ireland Rosenfeld/
Marcia Ireland Rosenfeld
Registration No. 60,679
McDonnell Boehnen Hulbert &
Berghoff LLP
300 South Wacker Drive
Chicago, Illinois 60606-6709
(312) 913-3319